Financial Report

Consolidated statement of changes in equity

1 January - 31 December

Attributable to shareholders of PolyPeptide Group AG:

 

 

 

 

 

 

 

 

kEUR

Share capital

Share premium

Translation reserve

Treasury shares

Other capital reserves

Retained earnings

Total

 

 

 

 

 

 

 

 

Balance as at 1 January 2021

33,000

2,340

-5,616

0

0

147,936

177,660

 

 

 

 

 

 

 

 

Result for the year

 

 

 

 

 

47,258

47,258

Remeasurement gain / (loss) on defined benefit plans, net of tax

 

 

 

 

 

833

833

Currency exchange differences

 

 

14,901

 

 

 

14,901

Total comprehensive income

0

0

14,901

0

0

48,091

62,992

 

 

 

 

 

 

 

 

Business restructuring

-33,000

33,000

 

 

 

 

0

Incorporation of PolyPeptide Group AG

273

 

 

 

 

 

273

Issue of new shares

29

182,112

 

 

 

 

182,141

IPO-related costs charged to equity

 

-4,652

 

 

 

 

-4,652

Purchase of own shares

 

 

 

-5,464

 

 

-5,464

Share-based payment

 

 

 

 

4,264

 

4,264

Transfer of own shares

 

 

 

4,277

-3,316

 

961

Repayment by Draupnir Holding B.V. related to IPO bonus

 

 

 

 

2,998

 

2,998

Total transactions with owners

-32,698

210,460

0

-1,187

3,946

0

180,520

Balance as at 31 December 2021

302

212,800

9,285

-1,187

3,946

196,027

421,173

kEUR

Share capital

Share premium

Translation reserve

Treasury shares

Other capital reserves

Retained earnings

Total

 

 

 

 

 

 

 

 

Balance as at 1 January 2020

33,000

2,340

-2,694

0

0

116,770

149,416

 

 

 

 

 

 

 

 

Result for the year

 

 

 

 

 

31,335

31,335

Remeasurement gain / (loss) on defined benefit plans, net of tax

 

 

 

 

 

-169

-169

Currency exchange differences

 

 

-2,922

 

 

 

-2,922

Total comprehensive income

0

0

-2,922

0

0

31,166

28,244

Balance as at 31 December 2020

33,000

2,340

-5,616

0

0

147,936

177,660